Sign In
Buy OKYO
$1.55
+0.0700 (+4.73%)
At Close: Jul 24, 2026
OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board
05:58am, Tuesday, 19'th May 2026
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has expanded its Scientific Advisory Board with the appointment of Dr. Marta Sacchetti as the company...
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
07:00am, Wednesday, 29'th Apr 2026
LONDON and NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neurop
OKYO Pharma to present at Eyecelerator, share urcosimod data at ARVO annual meeting
04:45am, Wednesday, 29'th Apr 2026
OKYO Pharma Ltd (NASDAQ:OKYO) said its CEO Robert Dempsey will present at Eyecelerator on May 1 in Denver, while company leadership will also participate in...
Gold mining pullback presents a compelling buying opportunity - broker
10:51am, Tuesday, 07'th Apr 2026
The sharp pullback in gold mining stocks has created a compelling buying opportunity, that's according to JP Morgan, with the broker arguing the sector’s...
OKYO Pharma advances clinical strategy with SAB meeting and ASCRS presentation
08:42am, Tuesday, 07'th Apr 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on treatments for neuropathic corneal pain (NCP) and inflammatory eye diseases, has announced plans to convene a Scien
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
07:00am, Tuesday, 07'th Apr 2026
LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa
OKYO Pharma Announces Chairman and Founder Acquires Shares
12:00pm, Thursday, 19'th Mar 2026
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neurop
OKYO Pharma Announces Director Acquires Shares
10:00am, Thursday, 19'th Mar 2026
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neurop
OKYO Pharma executive chairman increases stake with share purchase
08:12am, Thursday, 19'th Mar 2026
OKYO Pharma Ltd (NASDAQ:OKYO) said Panetta Partners, linked to its executive chairman Gabriele Cerrone, has purchased about 10,000 shares at $1.59 each,...
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
07:00am, Thursday, 19'th Mar 2026
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa
Alibaba Group reports revenue miss for December quarter, shares fall
06:08am, Thursday, 19'th Mar 2026
Alibaba Group (NYSE:BABA) reported weaker-than-expected results for its December quarter, as revenue fell short of forecasts and profits declined sharply,...
FTSE 100 Live: Stocks expected to slump as oil prices soar on Iran counterattacks
03:07am, Thursday, 19'th Mar 2026
7.16am: FTSE 100 called over 100 points lower as oil soars The FTSE 100 is expected to nosedive more than 100 points on Thursday morning as oil prices...
The Trade Desk under pressure after audit allegations, Jefferies flags growth risks
11:47am, Wednesday, 18'th Mar 2026
Jefferies analysts have struck a cautious tone on The Trade Desk (NASDAQ:TTD), warning that recent developments involving one of its largest agency partners...
OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial
09:03am, Wednesday, 18'th Mar 2026
OKYO Pharma Ltd (NASDAQ:OKYO) said on Wednesday it observed improvements in quality-of-life measures in patients treated with its experimental therapy urcosimod in a mid-stage study for neuropathic co
LONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neurop
